Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care

• by Yanfeng Song, Xiaofei Zhou, Lina Wang

• June 9, 2026

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

• by Philipp Berning, Markus Maulhardt, Hristo Boyadzhiev, Anca-Maria Albici, Snjezana Janjetovic, Anna Ossami Saidy, Christian Schultze-Florey, Simon Call, Friedrich Stölzel, Annamaria Brioli, Michael Daskalakis, Juliane Knust, Justin Hasenkamp, Rebecca Wurm-Kuczera, Alexander Pohlmann, Matthias Stelljes, Cyrus Khandanpour, Ulrike Bacher, Amelie Boquoi, Florian H. Heidel, Hans Christian Reinhardt, Gerald Wulf, Natalie Schub, Bastian von Tresckow, Georg Lenz, Thomas Pabst, Evgenii Shumilov

• June 2, 2026

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

• by Raffaella Greco, Isabel Sánchez-Ortega, Antonio M. Risitano, Krzysztof Kalwak, Annalisa Ruggeri, Iliana Kleovoulou, Marina Atlija, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Maria Ester Bernardo, Charles Crawley, Mette D. Hazenberg, Olaf Penack, Helen Baldomero, Jakob R. Passweg, Ibrahim Yakoub-Agha, Donal P. McLornan, Fabio Ciceri, Anna Sureda

• May 27, 2026

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

• March 30, 2026

• 2 min